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improves insulin resistance without adversely
affecting lipids or bodyweight in healthy adults:
a randomized free-living cross-over study
Todd C Rideout1*†, Christopher P F Marinangeli2†, Heather Martin2, Richard W Browne3 and Curtis B Rempel2*Abstract
Background: Given the highly debated role of dairy food consumption in modulating biomarkers of metabolic
syndrome, this study was conducted to examine the influence of long-term (6 month) dairy consumption on
metabolic parameters in healthy volunteers under free-living conditions without energy restriction.
Methods: Twenty-three healthy subjects completed a randomized, crossover trial of 12 months. Participants
consumed their habitual diets and were randomly assigned to one of two treatment groups: a high dairy
supplemented group instructed to consume 4 servings of dairy per day (HD); or a low dairy supplemented group
limited to no more than 2 servings of dairy per day (LD). Baseline, midpoint, and endpoint metabolic responses
were examined.
Results: Endpoint measurements of body weight and composition, energy expenditure, blood pressure, blood
glucose, and blood lipid and lipoprotein responses did not differ (p > 0.05) between the LD and HD groups. HD
consumption improved (p < 0.05) plasma insulin (−9%) and insulin resistance (−11%, p = 0.03) as estimated by
HOMA-IR compared with the LD group.
Conclusions: Study results suggest that high dairy consumption (4 servings/d) may improve insulin resistance
without negatively impacting bodyweight or lipid status under free-living conditions.
Trial registration: Clinical Trials.gov: NCT01761955
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Dairy has been an important component of the human
diet, mainly valued for its superior amino acid compos-
ition, high protein quality, and a source of calcium [1]. Be-
yond it’s macronutrient composition, low fat dairy foods
contain an array of health promoting bioactive compo-
nents including whey peptides, conjugated linoleic acid,
sphingolipids, oligosaccharides, and imunoglobulins [2].* Correspondence: rideout@buffalo.edu; rempelc@canolacouncil.org
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reproduction in any medium, provided the orHowever, despite this rich bioactive composition, the
health effects of dairy are highly disputed [3,4].
Increased dairy consumption has been demonstrated
to reduce obesity [5] and modulate metabolic distur-
bances including hyperinsulinemia [6] and blood pres-
sure [7,8]. Prospective cohort studies suggest that
consumption of low fat dairy products is associated with
a low incidence of type 2 diabetes compared with low
dairy diets [9-12]. A recent meta-analysis of 7 cohort
studies by Tong et al. [11] suggests that increased con-
sumption of total and low fat dairy products may reduce
the risk of type 2 diabetes by 5 and 10%, respectively.
This disease reduction potential may be linked with the
insulin sensitizing properties of dairy products as
Ruidavets et al. have reported that high consumption ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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insulin resistance (odds ratio 0.67) [13].
Alternatively, it has been suggested that long-term
high fat dairy consumption may underlie the pathogen-
esis of type II diabetes by promoting β-cell apoptosis
[14] and increase CVD risk by contributing to hyperlip-
idemia. These negative health responses may be linked
with increased intake of insulin-like growth factors (1 & 2)
[3] and saturated fat of dairy foods [15-17]. Inconsistent
data from different studies on the health benefits of dairy
may be attributed to differences in experimental design
(study population, health status, ethnicity, and gender)
[18] and differential health effects of specific dairy prod-
ucts [19]. Furthermore, it has been suggested that the
health promoting effects of increased dairy consumption,
particularly with respect to weight loss, may be associated
with an energy restricted diet [20]. Additional long-term
randomized controlled trials are needed to resolve the
current controversies regarding the effects of in-
creased dairy consumption on risk factors for type 2
diabetes, in addition to other metabolic health re-
sponses. Therefore, the aim of the present study was
to examine the long-term (6 months) effects of high
dairy consumption (4 servings per day) on metabolic
parameters in healthy volunteers under free-living
conditions without energy restriction or other lifestyle
modifications. The primary aim of this study was to
observe the effect of dairy consumption on metabolic
parameters including blood lipids, glucose, and insu-
lin. Secondary endpoints were body weight and com-
position, and energy expenditure.Methods
The study was conducted at the Clinical Nutrition Re-
search Unit at the Richardson Centre for Functional
Foods and Nutraceuticals (RCFFN), University of Mani-
toba between April 2009 – May 2011. Subjects were
recruited from the Winnipeg area via newspaper and
radio endorsements, poster advertisements, and flyer
distributions.Day 0 Mon
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Figure 1 Experimental design followed to examine metabolic responInclusion/exclusion criteria
Male and female subjects (18–75 years of age) were eli-
gible for study participation if they had a BMI between
18.5-35.0 kg/m2 and were assessed to be healthy based
on a pre-study screening examination including medical,
diet, and lifestyle history. Age and BMI inclusion ranges
were wide-ranging in anticipation of difficulty in
recruiting subjects for a 1-year intervention. Subjects
were excluded if pregnant; diagnosed with diabetes or
cardiovascular, liver, or renal disease; reported regular
use of appetite suppressants or Orlistat (Xenical) or ir-
regular use of other treatments which might interfere
with the outcomes of the study (e.g. anti-hypertensives,
statins, thyroxine, omega-3 supplements); reported ha-
bitual consumption of more than 1 ½ servings of dairy
per day; or were unable to consume 4 servings of low fat
dairy per day for 6 months due to known allergy or dairy
intolerance. To confirm individual health status and eli-
gibility, all subjects underwent a complete physical
examination conducted by the study physician.
Study design and protocol
The study protocol was approved by the Joint Faculty
Research Ethics Board (JFREB) at the University of
Manitoba. All subjects signed informed consent to par-
ticipate in the study.
The study was a randomized, crossover trial of 12
months with no washout period due to the length of
each study phase (Figure 1). At the onset of the study,
eligible participants (n = 39) were instructed to consume
their habitual diets and randomly assigned to one of two
treatment groups for 6 months using a random number
generator: a high dairy supplemented group instructed
to consume 4 servings dairy per day (HD); or a low dairy
supplemented group limited to no more than 2 serving
dairy per day (LD). At the end of the initial 6-month
phase, subjects initially randomized to the HD group
were switched to the LD treatment and vise versa for
the remainder of the study. The LD and HD serving
sizes were based on Canada’s Food Guide, which recom-
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se to consumption of low versus high dairy foods.
Table 2 Baseline characteristics of study subjects prior to
start of study1
Variable Mean ± SD
General characteristics
Age (y) 53 ± 12.26 (range 22–72)
Gender (M/F) 5/18
Height (m) 1.65 ± 0.08
Body weight (kg) 85.61 ± 10.30
Body mass index (kg/m2) 31.86 ± 3.01
Waist circumference (cm) 99.76 ± 9.83
Waist:hip 0.84 ± 0.07
Systolic blood pressure 125.34 ± 17.90
Diastolic blood pressure 77.82 ± 14.12
DEXA
Total body fat (%) 47.46 ± 4.51
Abdominal fat (%) 47.36 ± 8.03
Lean body mass (%) 50.95 ± 4.64
Plasma biochemistry
Glucose (mmol/L) 5.17 ± 0.68
Insulin (μU/mL) 15.37 ± 2.80
Total cholesterol (mmol/L) 5.73 ± 0.62
LDL-cholesterol (mmol/L) 3.49 ± 0.57
HDL-cholesterol (mmol/L) 1.42 ± 0.37
Triglycerides (mmol/L) 1.79 ± 0.54
ApoB (mg/dL) 85.56 ± 31.88
ApoE (mg/dL) 5.00 ± 1.66
Lp(a) (mg/dL) 52.20 ± 60.58
ApocII (mg/dL) 5.82 ± 2.57
Energy expenditure
Metabolic rate (kJ/min) 2.80 ± 0.50
Carbohydrate oxidation (g/min) 0.02 ± 0.04
Fat oxidation (g/min) 0.1 ± 0.02
1n = 23 for LD; n = 23 for HD.
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reported that 65-80% of Canadian adult consume less
than 2 servings per day [21]. Subjects assigned to the
HD group were regularly provided (every 2 weeks) with
standard servings of low fat dairy products (eg. 250 mL
milk, 175 g yogurt) for dietary incorporation as indicated
in Canada’s Food Guide. Subjects were instructed to
consume only those dairy products that were provided
by the research staff. During the HD phase, subjects
were asked to incorporate dairy products into their diets
by substitution so as not to increase their normal energy
intake. During the LD phase, subjects were instructed to
consume their normal diets but to not exceed more than
2 servings of dairy per day. Nutrient composition of the
low fat dairy products is presented in Table 1. Subjects
were instructed to maintain their normal diet and level
of physical activity for the duration of the study periods.
Beyond instructions as to how to incorporate dairy into
their daily diet, the subjects received no dietary counsel-
ing throughout the study period.
Data collection time points
At two separate points during each phase (4 and 6
months of each intervention phase), subjects were asked
to complete a food frequency questionnaire (adapted
from the National Institutes of Health Diet History
Questionnaire), physical activity diary, and 3-day mid-
week food record. To monitor compliance, subjects were
provided with a logbook and asked to record the num-
ber of dairy servings consumed each day. At baseline
and the end of each 6-month period, fasting measure-
ments of body weight, blood pressure, DEXA, and indir-
ect calorimetry were obtained. Furthermore, 12-h fasted
blood draws were collected for blood biochemistry
measurements at baseline, midpoint, and endpoint as
outlined in Figure 1. Subject anthropometric and meta-
bolic measurements taken prior to the start of the study
are provided in Table 2.Table 1 Macronutrient composition of low fat milk and
yogurt products provided to study subjects
Macronutrient Skim milk1 Yogurt1
Serving size 250 mL 100 g
Energy/serving (kJ) 370 180.03
Carbohydrate (g) 12.84 6
Sugar 13.18 6
Fiber 0 0
Protein (g) 8.72 4
Fat (g) 0.21 0.08
Saturates (g) 0.156 0
Trans fat (g) 0.008 0
1Provided by Aliments UTLIMA Foods Inc. / Yoplait, Granby, QC.Procedures
Blood collection and blood pressure
Twelve-hour fasting serum and plasma blood samples
were collected at the beginning and end of each study
phase. Blood was centrifuged at 3000 × g for 20 minutes
at 4°C to separate serum and plasma from erythrocytes,
which were then stored at −20°C for future analyses.
Resting blood pressure and heart rate (average of two
measurements) were recorded by automated oscillo-
metry with the subject in supine position.
Body composition protocol
Body composition, including percentage of total fat mass
(%TFM), TFM and total lean mass, as well as percentage
android and gynoid fat, were assessed at the start and
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X-ray absorptiometry (LunarProdigy Advance; GE Health-
care, Madison, WI, USA). Body composition data
including %TFM, TFM, and total lean mass were deter-
mined using Encore 2005 software version 9.30.044 (GE
Healthcare).
Energy expenditure
At the beginning and end of each study phase, fasting
energy expenditure was determined using open circuit
indirect calorimetry (Vmax Encore, Summit Technolo-
gies Inc, Burlington ON Canada) fitted with a ventilated
canopy. The flow sensor and gas sensors were calibrated
daily prior to initiating respiratory measurements. The
flow sensor was calibrated using a calibration syringe.
Gas sensors were automatically calibrated by Vmax En-
core software (Cardinal Health, Maple, ON Canada)
using two reference gasses with the first containing 16%
O2, 4% CO2 and 80% N2 and the second containing 26%
O2, 0% CO2 and 74% N2. All indirect calorimetry data
was collected using Vmax Encore software. Commence-
ment of pre-menopausal women into the study was
planned such that they did not undergo indirect calor-
imetry measurements during their menstrual cycle. In-
direct calorimetry measurements were taken for 30 min.
The first 15 min acted as a stabilization period, while
data from the latter 15 min was used to determine
fasting energy expenditure, fat oxidation and carbohy-
drate oxidation. The methodologies used to calculate
these measures are discussed elsewhere [22]. As subjects
were fasting, the constant 0.829 L O2/g glycogen was
used to calculate carbohydrate oxidation [23,24].
Blood biochemistry analyses
Plasma total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C), triglycerides (TG), and glucose
were determined by automated enzymatic methods
on a Vitros 350 chemistry analyzer (Ortho-Clinical
Diagnostics, Markham, Ontario, Canada). LDL-C con-
centrations were estimated by the difference method
using the Friedewald formula. Apolipoproteins were
measured by immunoturbidometric assay on a Pentra
400 autoanalyzer according to manufacturer’s instruc-
tions (Kamiya Biomedical Company, Seattle, WA, USA;
kits: ApoB, KAI-004; ApoE KAI-007; CII, KAI-005; Lp
(a), KAI-044). Serum insulin was analysed by ELISA
(EZHIASF-14K, Millipore, Billerica, MA). Insulin home-
ostasis modeling assessment (HOMA) was utilized as an
estimate for insulin resistance (IR). HOMA values were
calculated using previously outlined methods [25].
Statistical analysis
The study was powered based on previously reported
lipid responses following 21 weeks of high dairyconsumption [26,27]. A sample size of 20 subjects was
anticipated to detect a 19% reduction in blood TG
(alpha 0.05; 0.80 power). In anticipation of a large drop-
out rate due to the long study duration, 39 subjects were
recruited to begin the trial. Data were analyzed with a
linear mixed model ANOVA with subject as a random
factor. Baseline measurements of each phase were used
as covariates for endpoint measurements. Data were fur-
ther analyzed as percent change from baseline responses
for LD vs. HD phases. Macronutrient intake data col-
lected from mid-week 3-day food records were analyzed
with Food processor (Food processor, Salem, OR). All
data are presented as means ± SD and statistical signifi-
cance was set at p < 0.05 for all analyses. Data were ana-
lyzed using IBM SPSS software version 19.0 (SPSS, Inc.,
Chicago, IL, USA).
Results
One hundred and forty-four individuals initially
responded to the recruitment strategy that focused on
dairy as a diet intervention for improvement of
cardiometabolic risk factors. Of these 144 respondents,
51 individuals were screened and deemed eligible for the
trial, and 39 subjects agreed to participate. Of the initial
39 subjects that began the study, 23 completed both
study phases (n = 23 for both LD and HD). Subjects pro-
vided several reasons for dropping out of the study in-
cluding an inability to consume the required daily
amount of dairy (n = 2), personal family obligations (n =
13), and relocation (n = 1) (Figure 2). Baseline character-
istics of dropout subjects were not different (p > 0.05)
than those who completed the study (data not shown).
Macronutrient intake during the two periods did not
differ (p > 0.05) between the LD and HD groups
(Table 3). Calcium intake in the HD group tended to be
higher (p = 0.10) than the LD group whereas there was
no difference (p > 0.05) in vitamin D intake between
groups (Table 3).
Endpoint and percent change adjusted whole-body
and metabolic responses between the LD and HD
phases are presented in Table 4. Although no difference
(p > 0.05) was observed in blood glucose between the LD
and HD groups, HD consumption reduced (p < 0.05)
plasma insulin and improved (p < 0.05) insulin resistance
as estimated by HOMA-IR, (endpoint and percent change
Table 4). Endpoint and percent change variables in body
weight and body composition, energy expenditure, blood
pressure, and blood lipid and lipoprotein responses did
not differ (p > 0.05) between the LD and HD phases.
Discussion
The major finding of this study is that consumption of 4
servings/d of low-fat dairy milk and yogurt products
under free-living conditions for 6 months reduced
Subjects Screened 
n = 149
Received consent to 
participate in the trial. 
n = 39
Did not meet inclusion criteria (n=22) 
Did not agree to participate in the trial (n=83) 
Randomized to the low 
dairy treatment protocol 
n=20 
Randomized to the high 
dairy treatment protocol 
n=19 
6 month assessment  
& 
Initiation of low diary 
treatment protocol 
n=13 
6 month assessment  
& 
Initiation of high diary 
treatment protocol 
n=16 
12 month assessment 
n=13 




Personal reasons (n=3) 
Dropouts 
 Unable to adhere to 
protocol (n=2) 
Personal reasons (n=4) 
Dropouts 
Personal reasons (n=3) 
Dropouts 
Personal reasons (n=3) 
Figure 2 Subject recruitment and progression throughout the study.
Table 3 Selected daily nutrient intake estimated from
3-day mid-week food records1
Item Low dairy2 High dairy2
Total calories 2396 ± 430 2268 ± 502
Carbohydrate (% energy) 51.08 ± 6.93 54.13 ± 6.71
Fat (% energy) 34.06 ± 5.72 30.07 ± 4.75
Protein (% energy) 15.98 ± 3.29 15.81 ± 1.74
Total Carbohydrates (g) 299.66 ± 139.38 307.65 ± 83.07
Monosaccharides (g) 13.54 ± 10.11 10.87 ± 8.03
Disaccharides (g) 13.48 ± 4.76 8.92 ± 3.15
Total dietary fiber (g) 25.58 ± 9.04 23.79 ± 8.41
Total Fat (g) 94.55 ± 38.12 76.09 ± 22.08
Saturated fat (g) 26.72 ± 9.44 24.1 ± 8.52
Monounsaturated fat (g) 19.55 ± 9.97 15.06 ± 7.96
Polyunsaturated fat (g) 9.55 ± 3.37 8.74 ± 3.09
Cholesterol (mg) 273.29 ± 96.62 217.87 ± 77.03
Total Protein (g) 94.32 ± 42.83 88.14 ± 31.16
Vitamin D (μg) 4.77 ± 1.68 6.17 ± 2.18
Calcium (mg) 1024.31 ± 347.77 1222 ± 163.15
1Estimated from 3-day food records taken at 4 and 6 months of each
intervention phase.
2Mean ± SD; n = 23.
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ance (11%) in overweight and obese adults. Although the
long-term clinical implications of these results are un-
clear, fasting insulin and HOMA-IR have been shown to
be sensitive predictive markers of diabetes, ischemic
stroke, and coronary heart disease risk in the general
population as well as in at-risk subjects [28-32]. Previous
data from the Verona Diabetes Complications Study sug-
gest that every 1-unit increase in HOMA-IR is associ-
ated with an odds ratio of CVD incidence of 1.56 in
Type II diabetics [33]. This improvement in insulin re-
sistance may be protective in this population of over-
weight and obese individuals.
Our results are supported by dairy intervention studies
under both controlled feeding and free-living conditions.
Compared to a low dairy diet (<0.5 servings/d), a 12-
week study by Stancliffe et al. (2011) reported reductions
in fasting insulin and insulin resistance in a similar
population of overweight and obese subjects consuming
dairy as milk and yogurt (3.5 serving/d) [6]. Similar re-
sults were recently reported by Nikooyeh et al. (2011)
[34] in type 2 diabetics consuming 250 mL/day of plain,
vitamin D-fortified, or a vitamin D + calcium-fortified
yogurt drink. Moreover, results from a recent meta-
analysis and previous observational and prospective
Table 4 Metabolic parameters at the end of the 6 month low and high dairy phases
Variable
Endpoint % change Endpoint % change
LD1 LD2 HD1 HD2
Body weight (kg) 86.2 ± 8.6 2.1 ± 1.2 87.0 ± 8.2 2.4 ± 1.3
Waist circumference (cm) 100.7 ± 13.3 1.0 ± 2.3 98.2 ± 7.3 1.2 ± 2.2
Total body fat (%) 45.4 ± 9.4 1.9 ± 2.1 45.0 ± 8.6 2.7 ± 2.3
Abdominal fat (%) 44.8 ± 9.02 2.1 ± 2.62 44.9 ± 7.82 1.2 ± 1.53
Systolic blood pressure (mm/Hg) 124.1 ± 16.2 2.5 ± 3.2 121.5 ± 14.6 4.8 ± 2.5
Diastolic blood pressure (mm/Hg) 78.5 ± 16.0 0.7 ± 2.6 76.6 ± 9.4 2.3 ± 2.6
Glucose (mmol/L) 5.2 ± 0.7 3.8 ± 1.5 5.2 ± 0.7 2.1 ± 1.9
Insulin (μU/mL) 16.2 ± 3.7 10.0 ± 3.2 14.8 ± 2.4* 2.5 ± 2.2¥
HOMA-IR 3.8 ± 1.3 16.5 ± 4.6 3.4 ± 0.9* 5.1 ± 2.8¥
Total cholesterol (mmol/L) 5.4 ± 0.9 1.1 ± 3.1 5.6 ± 0.8 3.1 ± 2.4
LDL-cholesterol (mmol/L) 3.3 ± 0.8 −1.2 ± 2.1 3.4 ± 0.8 3.9 ± 5.1
HDL-cholesterol (mmol/L) 1.4 ± 0.3 4.6 ± 2.3 1.4 ± 0.4 8.4 ± 3.4
Triglycerides (mmol/L) 1.8 ± 0.7 −0.05 ± 8.7 1.7 ± 0.6 −3.8 ± 10.1
ApoB (mg/dl) 90.7 ± 20.1 2.1 ± 1.8 92.5 ± 19.6 3.2 ± 4.5
ApoE (mg/dl) 5.4 ± 0.5 −2.5 ± 1.1 5.3 ± 0.8 −4.8 ± 2.6
Lp(a) (mg/dl) 37.3 ± 37.9 −9.4 ± 6.2 48.1 ± 13.1 −0.05 ± 7.4
ApoCII (mg/dl) 6.5 ± 1.7 10.1 ± 3.9 6.2 ± 1.9 2.6 ± 3.9
Metabolic rate (kJ/min) 2.8 ± 0.7 1.0 ± 3.9 2.7 ± 0.8 4.9 ± 4.3
Carbohydrate oxidation (g/min) 0.01 ± 0.04 3.6 ± 1.7 0.03 ± 0.05 6.8 ± 3.2
Fat oxidation (g/min) 0.07 ± 0.02 3.8 ± 0.02 0.06 ± 0.02 9.6 ± 10.9
1Endpoint values adjusted for baseline levels within period; mean ± SD; n = 23 LD; n = 23 HD.
2% change from baseline values were calculated using phase 1, d-1.
*P < 0.05 compared with endpoint LD; ¥P < 0.05 compared with % change from baseline LD.
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lowering the incidence of type II diabetes and metabolic
syndrome [11,35-37].
Alternatively, a recently published 12-month cross-
over study examining the cardiometabolic health re-
sponses to increased dairy consumption by Crichton
et al. [38] did not observe an insulin sensitizing response
to HD vs. LD intake. This study was similar to the
present study in terms of design (crossover), length (6
month), dairy servings (HD, 4 servings/d vs. LD, ≤ 1
servings/d), and study population (overweight and
obese). However, while our study limited dairy products
to low fat milk and yogurt, the study design by Crichton
et al. was more inclusive by incorporating low fat fla-
vored milk and yogurt, vanilla custard, and a limited
amount (no more than 7 servings/week) of cheese
(sliced, cottage, ricotta, cream), ice cream, butter, and
margarine. We deliberately utilized milk and yogurt as
treatments because these dairy products have reasonably
long expiration dates, are easily portable, and can be
readily incorporated into the diet. Depending on ingredi-
ent composition, formulation, and manufacturing
process, dairy products have a broad range of textural
and physiochemical properties. These differences greatlyinfluence the bioavailability of dairy-derived nutrients
and bioactive compounds and may ultimately affect the
magnitude and direction of health responses following
their consumption. Although our results suggest that
consumption of dairy foods in the form of milk and
yogurt may have beneficial cardiometabolic effects, it is
difficult to speculate if similar responses would be ob-
served in response to the consumption of other dairy
foods. Ivey et al. (2011) [19] recently reported that, com-
pared to milk and cheese, yogurt consumption decreased
carotid artery intima-media thickness in elderly women.
Thus, studies designed to specifically examine health re-
sponses to different whole dairy foods and isolated dairy
food bioactive components are clearly warranted.
Numerous milk-derived bioactive compounds may
contribute to the insulin-sensitizing effects of dairy in-
cluding calcium, vitamin D, whole whey protein, and
fractionated peptides [39,40]. Vitamin D is well recog-
nized in sensitizing insulin responses through multiple
purported mechanisms which include regulation of insu-
lin receptor expression and stimulation of insulin release
by pancreatic β-cells [41,42]. Although both milk and
yogurt products used in the present study were vitamin
D fortified as stipulated under Canadian federal law, we
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LD and HD phases, suggesting that the insulin sensitiz-
ing response to increased dairy intake was independent
of vitamin D consumption. However, as this study was
designed as free-living and assessed nutrient intake using
food records, it is subject to design limitations including
poor dietary recall [43,44]. Limitations of dietary recall
during the 3-day food record may also be responsible for
the tendency (p = 0.1) observed in calcium intake be-
tween the HD (1222 mg) and LD (1024 mg) groups.
Given that the present study was designed to examine
the combined health response to low-fat milk and yogurt
whole foods, we cannot partition the effects of the spe-
cific dairy foods or identify the particular bioactive com-
ponent(s) that may be responsible for the protective
effects against increased insulin resistance. The vast ma-
jority of studies examining the influence of dairy con-
sumption on biomarkers of metabolic syndrome have
been conducted with whole dairy foods with very few
studies designed to partition the specific health effects of
isolated dairy components. One notable exception is a re-
cent study by Palacios et al. (2011) [26] who reported no
change in body composition or serum lipids in obese sub-
jects instructed to consume low calorie diets providing
~1200 mg/d calcium from dairy or calcium supplements.
Concerns have been raised that high dairy consump-
tion may be associated with an increased risk of
dyslipidemia and obesity [3]. However, the results of this
study lend further support to a growing clinical trial
database suggesting that low fat dairy foods can be in-
corporated into diets without adversely raising blood
lipids [38,45-47]. Similarly, there is no clear consensus of
the long-term effects of dairy consumption on body
weight and body composition, with reports of both in-
creased [48], decreased [49-51], and neutral [52,53] body
weight changes following dairy consumption. A recent
systematic literature review by Kratz et al. examining 16
studies [54] found little support for the hypothesis that
increased dairy fat or high fat dairy food consumption
contributes to increased adiposity. Similarly, a meta-
analysis from Chen et al. [55] using 29 RCT recently ex-
amined the effects of dairy consumption on body weight
and body fat mass. Their results suggest that dairy con-
sumption may not be associated with weight gain, but
may have a modest effect in facilitating weight loss in
energy restricted and short-term (<1 yr) intervention
studies. Results from the present 6 month study demon-
strate that, under free-living conditions and without en-
ergy restriction, long-term low-fat dairy consumption
does not alter body weight, body composition or energy
expenditure. These results further suggest that the insu-
lin sensitizing effects of dairy consumption are not re-
lated to body fat loss or factors that modulate energy
metabolism.There are several limitations to this study. First, it
proved difficult to sustain volunteer interest over such a
long trial duration and only 23 subjects of the original
39 fully completed each of the study phases (41%
dropout rate); however, we were able to retain our de-
sired target of 20 subjects. Interestingly, the previously
discussed study by Crichton et al. [38] with a similar de-
sign to ours also had a high drop-out rate (49%), which
suggests that future studies involving high dairy con-
sumption may benefit from a parallel arm design. Until a
similar study is repeated with a larger study population,
our results should be interpreted with caution. Second,
although volunteers were given log books to record their
daily dairy intake, these records were not reviewed by
the study staff until the end of the study, at which point
it was determined that they were incomplete. Therefore,
the lack of a compliance evaluation and actual dairy in-
takes are a major limitation of the current study. Third,
subjects were provided with dairy products during the
HD phase but were not provided with dairy-free foods
of comparable macronutrient composition during the
LD phase. This could have resulted in differences in food
intake and/or macronutrient balance between the two
phases beyond the sensitivity of the dietary analysis
conducted.Conclusions
In conclusion, the current study suggests that under
free-living conditions, consumption of 4 servings/d of
low-fat dairy milk and yogurt products for 6 months
may improve insulin resistance without negatively
impacting bodyweight or lipid status. These results re-
quire verification from additional long-term studies with
appropriate measures to increase subject retention. Fu-
ture studies should also be designed to further examine
the metabolic effects of specific dairy products and/or
dairy-derived bioactive components.
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